Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. two-birds

TWO-BIRDS SIGNED

A feasibility study for SYT-510, a first-in-class drug to treat neuropsychiatric disorders through restoring overall balance in brain chemistry

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TWO-BIRDS project word cloud

Explore the words cloud of the TWO-BIRDS project. It provides you a very rough idea of what is the project "TWO-BIRDS" about.

510    unforgiving    coerced    partnering    compound    neural    market    triggers    termed    regulatory    mechanism    seris    safety    anti    relive    post    thereby    selective    unfortunately    patient    thoughts    understand    ready    people    population    reuptake    symptoms    chemistry    severe    regulate    flashbacks    companies    commercialize    dependency    15    combined    ptsd    traumatic    provoke    hold    consolidate    psychological    70    clinician    disorder    anxiety    inhibitors    neuroregulator    syt    pharmacokinetic    modulate    action    pharma    clinical    stress    circuit    establishing    attractive    drugs    safe    master    nightmares    experiences    chemistries    ineffective    self    synendos    drug    molecule    balance    never    feasibility    risk    small    patients    demonstrated    family    relief    endocx    pharmaceutical    dysregulated    victims    million    final    stage    deals    paradigm    birds    preclinical    sales    plan    circuits    restoring    restore    business    treatment    sustainable    limiting    brain    first    endocannabinoid    start    manner    disrepair    cognitive    profile    function    trauma    intrusive    eventual    investor    disorders    downstream    co   

Project "TWO-BIRDS" data sheet

The following table provides information about the project.

Coordinator		 SYNENDOS THERAPEUTICS AG 

Organization address
address: SWISS INNOVATION PARK, GEWERBESTRASSE 24
city: ALLSCHWIL
postcode: 4123
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYNENDOS THERAPEUTICS AG CH (ALLSCHWIL) coordinator 50˙000.00

Map

 Project objective

PTSD affects over 15 million people in Europe. So far, 70% never find relief. New drugs that restore the endocannabinoid (endoCx) neural circuit hold potential to change this paradigm.

Post-traumatic stress disorder, known as PTSD, is one of the most unforgiving psychological disorders. As victims of trauma, PTSD patients are coerced by their dysregulated brain chemistries to relive their traumatic experiences, where specific triggers provoke symptoms such as flashbacks, intrusive thoughts, nightmares and severe anxiety. Unfortunately, current drugs address only specific downstream neural circuits and are highly ineffective. The endoCx is highly dysregulated in PTSD, and as a 'master neuroregulator', drugs that restore its function in a safe and sustainable manner have strong potential to be the first effective treatment for PTSD.

Synendos is a pharmaceutical start-up who have identified a new family of drugs that modulate the endoCx via a new mechanism-of-action. Termed SERIs, or, ‘selective endocannabinoid reuptake inhibitors’, these small molecule drugs regulate the endoCx system in a self-limiting manner, thereby restoring balance to brain chemistry without risk of drug dependency or cognitive disrepair. Our lead compound SYT-510 is at the stage of preclinical development, where it has demonstrated effective anti-anxiety activity, favourable pharmacokinetic characteristics and a strong safety profile.

We aim to commercialize SYT-510 through establishing partnering deals with pharma companies for its co-development and eventual sales. With a patient population of over 30 million (in EU/US combined), PTSD is an attractive market for drug development.

TWO-BIRDS project: The main aims of this feasibility study are to 1) work to further understand clinician and patient needs, 2) define a detailed plan for final preclinical, clinical and regulatory activities and 3) consolidate new information into an investor-ready business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TWO-BIRDS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TWO-BIRDS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More